Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

NCT06427330 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoid Leukemia

Interventions

DRUG: Inotuzumab ozogamicin

Sponsor

Institute of Hematology & Blood Diseases Hospital, China